Skip to main content
. 2022 Sep 20;23(19):11013. doi: 10.3390/ijms231911013

Figure 2.

Figure 2

The effect of ADAM10 inhibitor (GI254023X) or ADAM17 inhibitor (TAPI-1) on the release of TNF-α, TNFR-1 and IL-6R by constitutively and under inflammation BV2 microglia. BV2 microglia were incubated with GI254023X (5 μM) or TAPI-1 (25 μM) for 24 h in the absence or presence of 1000 ng/mL LPS. The medium was collected for ELISA measurements and cell lysates were lysed for WB analysis. The concentration of TNF-α (A), sTNFR-1 (B), IL-6 (C) and sIL-6R (D) released in medium (n = 6 from 6 independent experiments). (E) The representative immunoblots of ADAM10 protein expression in BV2 cell lysate. (F–H) The quantification of ADAM10 expression in BV2 cell lysate (n = 10 from 5 independent experiments). (I) The representative immunoblots of ADAM17 expression in BV2 cell lysate. (J) The quantification results of ADAM17 in BV2 cell lysate (n = 8 from 4 independent experiments). Calnexin was used as a loading control. Black: constitutive cytokine release or protein expression set at 1; red: LPS-induced cytokine release or protein expression; blue: effect of ADAMs inhibitor on constitutive cytokine release or protein expression; green: effect of ADAMs inhibitor on LPS-induced cytokine release or protein expression. Results were expressed as mean ± SEM. * p < 0.05, ** p < 0.01 *** p < 0.001, **** p < 0.0001.